Kailera Therapeutics News and Activities

Kailera Therapeutics is one of the...

• Russell 3000.

Kailera Therapeutics is a company listed under the stock ticker KLRA (US).

Acquisition, funding and merger involving Kailera Therapeutics.

• Kailera Therapeutics has just announced a $625 Million fundraising (posted on April 17 2026).
• Kailera Therapeutics is now listed under ticker KLRA. (posted on April 17 2026).
• Kailera Therapeutics has just announced a $600 Million fundraising (posted on October 21 2025).
• Kailera Therapeutics has just announced a $400 Million fundraising (posted on October 4 2024).
• See more news about Kailera Therapeutics Hide news involving Kailera Therapeutics

View the org chart displaying its 32 main executives

Most searched biographies at Kailera Therapeutics

• Ron Renaud, President and Chief Executive Officer
• Martin Mackay, Director
• Yuting Liu, Director

Popular executive movements at Kailera Therapeutics

• Kathleen Tregoning has joined the company as Chief Corporate Affairs Officer  (posted on June 29 2026).
• Doug Pagan has joined the company as Chief Financial Officer  (posted on January 6 2026).
• Laurie Stelzer, Chief Financial Officer, has left the company  (posted on November 4 2025).

Click here to view some more movements at Kailera Therapeutics

Create your alert
to follow the executive moves at Kailera Therapeutics.

Kailera Therapeutics has 2,430 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Tempus has announced the acquisition of Personalis  (posted on July 20 2026).
• Eli Lilly has announced the acquisition of AtaiBeckley  (posted on July 17 2026).
• GSK has acquired Nuvalent (posted on July 17 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Kailera Therapeutics

• Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535 | Tue, 07/07/2026 - 07:00
• Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer | Mon, 06/29/2026 - 07:30
• Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026 | Fri, 06/05/2026 - 19:32
• Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference | Thu, 05/28/2026 - 16:05
• Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates | Tue, 05/26/2026 - 16:02
• Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions | Wed, 05/13/2026 - 07:30
• Kailera Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Mon, 04/20/2026 - 16:06
• Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide - Kailera
• Kailera | GLP-1 Therapies for Obesity Care | Press Releases
• Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531) - Kailera
• View more press releases Close

Social media about Kailera Therapeutics

• Kailera Therapeutics on Wikipedia, Google News & Yahoo Finance
• Kailera Therapeutics on LinkedIn, X (Twitter) & YouTube